Skip to main content

Table 4 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with chemotherapy

From: Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Study name/code (NCT) Study phase Type of Cancer Treatment Patients evaluated for response Time to first tumor assessment (weeks) ORR by RECIST 1.1 criteria ORR by immune-related response criteria Patients treated beyond progression Response rate after initial PD First author and date of publication
CheckMate-012
(NCT01454102)
1 NSCLC Nivolumab plus standard chemotherapy 56 10a 24 (42.9%) Not reported Not reported 1 (1.8%) Rizvi 2016 [80]
GP28328
(NCT01633970)
1b Breast cancer Atezolizumab plus chemotherapy 33 8 13 (39.4%) Not reported 6 (18.2%) 3 (9.1%) Adams 2019 [81]
PembroPlus
(NCT02331251)
1b/2 Pancreatic adenocarcinoma Pembrolizumab plus gemcitabine and nab-paclitaxel 15 Not reported 3 (20.0%) 3 (20.0%)a Not reported 0 (0.0%)b Weiss 2017 [82]
NCI-2015-01310
(NCT02538510)
2 HNSCC and salivary gland cancer Pembrolizumab plus vorinostat 50 9 12 (24.0%) Not reported 12 (24.0%) 1 (2.0%)c Rodriguez 2019 [83]
PEMBROSARC
(NCT02406781)
2 Sarcomas Pembrolizumab plus CP 50 6 0 (0.0%) 1 (2.0%) Not reported 1 (2.0%) Toulmonde 2018 [84]
  1. Abbreviations: CP cyclophosphamide, HNSCC head and neck squamous cell carcinoma, NCT ClinicalTrials.gov Identifier, NSCLC non-small-cell lung carcinoma, ORR overall response rate, PD progressive disease, SD stable disease
  2. a Per the original study protocol, tumor response was first assessed at week 6. However, due to the chance of early pseudoprogression at this time point, the protocol was amended to perform the first tumor assessment at week 10
  3. b2 patients achieved immune-related SD after RECIST-defined PD
  4. can additional patient achieved > 6 months SD